Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease Brown VI; Seif AE; Reid GS; Teachey DT; Grupp SAImmunol Res 2008[]; 42 (1-3): 84-105While the outcome for pediatric patients with lymphoproliferative disorders (LPD) or lymphoid malignancies, such as acute lymphoblastic leukemia (ALL), has improved dramatically, patients often suffer from therapeutic sequelae. Additionally, despite intensified treatment, the prognosis remains dismal for patients with refractory or relapsed disease. Thus, novel biologically targeted treatment approaches are needed. These targets can be identified by understanding how a loss of lymphocyte homeostasis can result in LPD or ALL. Herein, we review potential molecular and cellular therapeutic strategies that (i) target key signaling networks (e.g., PI3K/AKT/mTOR, JAK/STAT, Notch1, and SRC kinase family-containing pathways) which regulate lymphocyte growth, survival, and function; (ii) block the interaction of ALL cells with stromal cells or lymphoid growth factors secreted by the bone marrow microenvironment; or (iii) stimulate innate and adaptive immune responses.|Adjuvants, Immunologic/therapeutic use[MESH]|Animals[MESH]|Enzyme Inhibitors/therapeutic use[MESH]|Humans[MESH]|Immunotherapy/methods[MESH]|Lymphoproliferative Disorders/metabolism/*therapy[MESH]|Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism/*therapy[MESH]|Protein Kinases/metabolism[MESH]|Receptor, Notch1/metabolism[MESH]|Signal Transduction/*drug effects[MESH]|TOR Serine-Threonine Kinases[MESH] |